[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

about

[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].

P2860

Q55447850-78C7F67C-E7C1-4901-8D38-16D1A83B69F1

P2860

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

Item

http://www.wikidata.org/entity/Q55425187

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@en

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@nl

type

Item

label

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@en

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@nl

prefLabel

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@en

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@nl

P1476

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

@en

P2093

Baorui Liu

http://www.w3.org/2001/XMLSchema#string

Xiaoping Qian

http://www.w3.org/2001/XMLSchema#string

Ying Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.

Genetic transfer of PNAS-4 induces apoptosis and enhances sensitivity to gemcitabine in lung cancer.

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.

Influence of genetic markers on survival in non-small cell lung cancer.

Pharmacogenomics and gemcitabine.

The role of BRCA1 in transcriptional regulation and cell cycle control.

P304

421-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2011.05.08

http://www.w3.org/2001/XMLSchema#string

P407

Chinese

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21569648

http://www.w3.org/2001/XMLSchema#string

P932

6000321

http://www.w3.org/2001/XMLSchema#string

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

about

P2860

P2860

[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932